Takeda Reports Results for Three Quarters (April-December) of FY2015,Reaffirms Management Guidance for the Full Year
Takeda Pharmaceutical Company Limited (TOKYO:4502):
Results of April to December period reaffirms full-year management guidance
- Underlying revenue +3.8% year-to-year (reported revenue growing +4.0% to 1,393.3 billion yen), led by strong performance in the U.S. and the emerging markets
- Underlying Core Earnings +1.5% year-to-year (operating profit -15.9% to 167.5 billion yen)
- Underlying Core EPS +17.3% year-to year (reported EPS growing +43% to 145 yen)
Contribution of Takeda's growth drivers
- Consolidated underlying revenue of gastroenterology, oncology and emerging markets – Takeda's growth drivers – is +8.5% year-to-year
- Gastroenterology underlying revenue +24.7%, oncology up +0.4% year-to-year
- Emerging markets underlying revenue +5.7% year-to-year, with particularly strong contributions from Russia and China
Growth of innovative new products to offset loss of exclusivity impact
- ENTYVIO® is on the way to over $2 bln in peak sales, BRINTELLIX® and ADCETRIS® show steady growth
- AZILVA® and LOTRIGA® are contributing to Japan business.
Efficiency gains continue
- Project Summit achieved 21 billion yen of cost savings in the April-December 2015 period, exceeding the full-year target
For FY2015 full year reported forecast, operating profit upgraded, others unchanged
- Based on performance through three quarters, Takeda raised the full year reported forecast for operating profit to 120 billion yen
Affirming management guidance in FY2015
- Low single-digit underlying revenue growth in FY2015, with underlying core earnings growth higher than underlying revenue growth, and underlying core EPS growth higher than underlying core earnings growth
Christophe Weber, President and Chief Executive Officer of Takeda,
"Through three quarters (April to December) of FY2015, Takeda's turnaround continues, with underlying revenue growth of +3.8% year-to-year, led by our growth drivers of gastroenterology, oncology and emerging markets. With the global launch of new products such as ENTYVIO and NINLARO, Takeda is on the right track to deliver revenue growth and improved profitability. On the basis of our three quarters results, we confirm our full-year management guidance."
Key figures for three quarters
|FY 2014||FY 2015||Growth|
|Core Earnings 1||276.5||269.8||-2.4%||+1.5%|
|Net Profit 3||79.7||113.6||+42.5%||–|
|EPS||101 yen||145 yen||+43.0%||–|
|Core EPS||216 yen||241 yen||+11.4%||+17.3%|
|Core Earnings is calculated from operating profit by excluding the impact of exceptional items, such as purchase accounting, amortization and impairment loss of intangible assets, restructuring costs and major litigation costs.|
|Underlying performance aims at understanding the real performance of the business. Underlying Revenue and Underlying Core Earnings excludes the same as above and adjusted for acquisitions/divestments and foreign exchange.|
|Attributable to the owners of the company|
Underlying revenue growth in the 3Q (April to December, 2015) was +3.8% year-to-year, Underlying Core Earnings was +1.5% and Underlying Core EPS was +17.3%, with no change in Takeda's management guidance for FY2015. Reported revenue grew +4.0% year-to-year to 1,393.3 billion yen. An increase in expenses to new global products as well as a decrease in other income such as reversal of COLCRYS® contingent consideration and gain from sales of real estate in 2014, resulted in a year-to-year decline in Operating Profit by 31.6 billion yen. Despite the decrease in operating profit, consolidated net profit was 113.6 billion yen, an increase of 33.9 billion yen (+42.5% year-to-year), mainly due to the decrease in income tax expenses.
Underlying revenue growth was mainly driven by Takeda's growth drivers; gastroenterology, oncology and emerging markets. The three account for almost 50% of Takeda's revenue. Gastroenterology grew by +24.7% year-to-year, driven by ENTYVIO®. Oncology revenue, including VELCADE® and ADCETRIS®, increased by +0.4%. Launched in the U.S. in December, NINLARO®, a highly innovative once-weekly capsule for multiple myeloma, is expected to provide a significant contribution to Takeda's mid- to long-term sustained growth. Emerging Markets revenue grew by +5.7% year-to-year, led by Value Brands (branded generics and Over-The-Counter medicines), with strong growth in Russia and China. Performance in the U.S. (+11.6% year-to-year underlying revenue growth) also contributed to revenue growth. In Japan, under the increasing generic pressure, underlying revenue declined -1.7% year-to-year, but the year-to-year revenue declines moderated, led by the contribution of AZILVA® and LOTRIGA®.
Project Summit – a company-wide strategic initiative to increase efficiency – continued to produce results, with 21 billion yen savings in the three quarters period, exceeding the full year target.
ENTYVIO® and NINLARO® are expected to be key global contributors to Takeda's sales growth. In Japan, a new business venture with Teva Pharmaceutical Industries Ltd. will be established in or after April 2016 to deliver Teva's high-quality generic medicines and Takeda's long-listed products to patients. It is expected to meet wide-ranged needs of patients and correspond to the growing importance of generics in Japan, while Takeda will further focus on innovative new medicines, such as AZILVA®, LOTRIGA®, TAKECAB®, NESINA® and ZAFATEK®.
As part of its ongoing effort to improve the R&D productivity, Takeda announced that its top priority is to be a leader in three therapeutic areas, Oncology, Gastroenterology and Central Nervous System. In addition, it will deliver maximum, targeted value in Specialty CV and an innovative business and global health approach in Vaccines.
Takeda affirmed its management guidance for FY2015, leading to long-term sales and profit growth, and raised the full-year reported forecast of operating profit to 120 billion yen, based on the three quarters' results.
Management Guidance for FY2015
|Underlying Revenue||Low single digit|
|Underlying Core Earnings||Higher than underlying revenue growth|
|Underlying Core EPS||Higher than underlying core earnings growth|
FY2015 full year reported
forecast: operating profit revised, others unchanged
|Profit before tax||115.0||–||115.0|
|Net profit for the year||68.0||–||68.0|
|EPS||87 yen||–||87 yen|
For more details on Takeda’s FY2015 3Q results and other financial information, please visit http://www.takeda.com/investor-information/results/
About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda (TOKYO:4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Information about Takeda is available on www.takeda.com.
Takeda Pharmaceutical Company Limited
Noriko Higuchi, +81-(0)3-3278-2306
Tsuyoshi Tada, +81 (0)3-3278-2417,
Media outside Japan
Jocelyn Gerst, +1-224-554-5542
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease15.12.2017 12:34 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in conjunction with the Committee for Advanced Therapies (CAT), has adopted a positive opinion recommending a marketing authorization (MA) for investigational compound Cx601 (darvadstrocel). Cx601 is expected to be indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.2 This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP opinion in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/201712
Bitcoin Romania and Twispay Announce Integration Partnership Providing Users with the Ability to Purchase Bitcoin with Bank Cards15.12.2017 12:21 | Pressemelding
Bitcoin Romania, leading Eastern European Bitcoin exchange & brokerage firm, and Twispay, Swiss-owned European payment processor and FinTech pioneer, today announced the availability of a payment integration that allows a global clientele to acquire Bitcoin and Ethereum cryptocurrencies using Visa and Mastercard bank cards. Unprecedented in Romania, this is one of the first East-Central European integration partnerships that allow consumers to use their cards to purchase cryptocurrency. Until recently, investors could only acquire cryptocurrencies through bank transfers and cash deposits, but the volatility of cryptocurrency markets dictates the need for additional operational flexibility. Investors require faster, safer, more reliable, and more comfortable ways to complete purchases. “One minute can make the difference between a million lost and a million earned. That is pr
Upon Conclusion of the Fourth Annual Forum for Promoting Peace in Muslim Societies, Scholars and Intellectuals Visit the Louvre Abu Dhabi Museum15.12.2017 11:38 | Pressemelding
A high-level delegation of dignitaries, scholars and intellectuals participating in the fourth annual Forum for Promoting Peace in Muslim Societies, visited the Louvre Abu Dhabi museum. The delegation was headed by H.E Mustafa Ceric, former Grand Mufti of Bosnia; alongside Sheikh Mohammad Mukhtar Ould Imbala, Head of Mauritania’s Fatwa & Grievances Supreme Council; H.E Amar Mirghani Hussein, Sudanese Minister of (religious) Guidance and Endowments; and H.E Salho Jay, Imam of the Juma Masjid in South Africa. The Forum was held in Abu Dhabi from 11-13 December 2017, with the participation of more than 700 scholars, intellectuals and religious dignitaries from around the world. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171215005255/en/ Group Photo of the Scholars and Intellectuals during their visit to the L
Kennedy Wilson Acquires 124-Unit Northbank Apartments in Dublin, Ireland for €45 Million15.12.2017 11:00 | Pressemelding
Global real estate investment company Kennedy Wilson (NYSE: KW) announces that it has acquired Northbank Apartments, a wholly-owned 124-unit apartment community in Dublin’s North Docks, for €45 million from Jarmar Properties Limited (In Receivership) acting through David Carson of Deloitte as Statutory Receiver, the lender being the National Asset Management Agency (“NAMA”). Situated in Dublin’s North Docks, Northbank is located just 50 meters from Kennedy Wilson’s existing 84-unit Liffey Trust apartments. The two buildings benefit from great transport links as the LUAS Red line is immediately adjacent connecting to Dublin’s city centre and main train stations in five minutes. “The successful acquisition of Northbank in such close proximity to our Liffey Trust asset allows us to leverage our existing presence and implement our value-add asset management strategy, including a
AML BitCoin Enters Phase II of ICO15.12.2017 09:00 | Pressemelding
NAC Foundation, LLC announces today that the initial coin offering for the AML BitCoin – the world’s only patent-pending compliant digital currency – has been extended for another month to accommodate a torrent of last minute, new coin purchasers and the demands of thousands of current owners of the coin, who have had difficulty navigating the process of establishing the specialized wallet required to hold the innovative digital currency. This second phase of the AML BitCoin initial coin offering will see an increase in the price of the coin, from US $1.00 to US $1.25. The company has already been contacted by prospective purchasers in the slightly higher priced Phase II, and anticipates a further price increase to US $1.50 within a week or two. HitBTC, one of the world’s largest and most active digital currency exchanges, was prepared to list the AML BitCoin for trading on
Joensuu City Challenge – International Competition for Innovative SMEs Opened15.12.2017 08:24 | Pressemelding
City of Joensuu, Finland, has announced an international competition in which 200,000 euros will be used for innovative pilot projects in the city centre. Joensuu has defined four city platforms on which companies or other interested organizations are invited to present innovative proposals. The winning proposals will be implemented as pilot projects in Joensuu. The deadline for the proposals is 18th March 2018. The implementation phase of the proposals should be carried out by May 2019. Competition information is provided in English, and proposals can be made in English and Finnish. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171215005170/en/ Joensuu City Challenge - International Competition for Innovative SMEs Opened (Photo: Business Wire) The four challenges for which solutions are sought are v
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom